In the phase 1 CT-0508 trial (NCT04660929), an anti-HER2 CAR-M demonstrated tumor trafficking, antigen-specific phagocytosis, and microenvironmental remodeling in patients with advanced HER2-positive malignancies, achieving stable disease in 44% of HER2 3+ tumors without dose-limiting toxicity, severe cytokine release syndrome, or neurotoxicity (94). The gene discussed is ERBB2; the disease is neoplasm.